Evidence map›Paper›PMID 42465903›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Germline determinants of risk and molecular subtype in young-onset lung cancer.

Jaclyn LoPiccolo, Ryan L Collins, Noah Fields, Carter Nakagawa, Kodi Taraszka, Xinan Wang, Li Su, Diane R Koeller, Alison Levine Schwartz, Alicia Charleston Pollaci and 22 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Jaclyn LoPiccoloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-0043-0206
Ryan L CollinsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1268-9995
Noah FieldsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0008-7650-9117
Carter NakagawaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kodi TaraszkaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Xinan WangHarvard Medical School, Boston, MA, USA.
Li SuHarvard Medical School, Boston, MA, USA.
Diane R KoellerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Alison Levine SchwartzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Alicia Charleston PollaciDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sarah M YoungLabcorp (formerly Invitae Corp), San Francisco, CA, USA.
Victoria G WilliamsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jose A AvilaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Emma VolignyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tom NguyenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andy J PangilinanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Richard M ErwinAddario Lung Cancer Medical Institute (ALCMI), San Carlos, CA, USA.
Barbara J GitlitzUniversity of Southern California/Norris Cancer Center, Los Angeles, CA, USA.
Silvia NovelloUniversity of Turin, Department of Oncology, AOU San Luigi, Orbassano (Turin), Italy.
Geoffrey R OxnardDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ugonma N ChukwuekeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Priscilla K BrastianosHarvard Medical School, Boston, MA, USA.
Ayal A AizerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Mizuki Nishino HatabuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Narjust FlorezDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kevin M HaigisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-0201-4444
Jorge J NievaAddario Lung Cancer Medical Institute (ALCMI), San Carlos, CA, USA.
Judy E GarberDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
David C ChristianiHarvard Medical School, Boston, MA, USA.
Pasi A JänneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Alexander GusevDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Funding

Dissecting the Role of Germline Genetics in RAS-Driven CancersR00CA286805 · NCI · DANA-FARBER CANCER INST · PI Ryan Lewis Collins · 2025 to 2026
$436k
Dissecting the Role of Germline Genetics in RAS-Driven CancersK99CA286805 · NCI · DANA-FARBER CANCER INST · PI COLLINS, RYAN LEWIS · 2024 to 2025
$327k
NCI NIH HHS K99 CA286805NCI NIH HHS R00 CA286805
6 · The paper itself

Abstract

Young-onset lung cancer is enriched for never-smoking and oncogene-driven tumors, yet its inherited genetic basis remains poorly defined. We performed germline whole-genome sequencing in 251 young-onset lung cancer cases (median age 37), which we jointly analyzed with never-smoking cases (n=196; median age 68) and cancer-free controls (n=1,883). We identified enrichments of rare deleterious coding variants across 55 cancer-related gene sets, including

Identifiers

PMID42465903
PMCPMC13370489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.